rEVO Biologics is a rare disease company delivering on the promise of recombinant medicine. By eliminating the barriers of limited access and production, we bring therapeutics to the market that make a real difference in the lives of patients.
Our track record of commercialization success started in the area of hereditary antithrombin deficiency with the strong sales growth and significant market share gains of our first product, ATryn® Antithrombin (Recombinant). And today we're growing even further with more products, as well as new indications for ATryn. Our ongoing clinical trials are opening access to even larger markets in underserved therapeutic classes with high patient needs.
Our groundbreaking approach to therapeutics enables expanded access to innovative therapies for the treatment of hematology, oncology, autoimmune and genetic diseases. The results are nothing short of remarkable. Better therapeutics, better economics, better outcomes. rEVO Biologics is committed to taking a different approach to better.
February 15, 2013 FRAMINGHAM, Mass, FEBRUARY 15, 2013 — rEVO Biologics announced today the results of a major retrospective study analysis of its pivotal phase 3 studies... Read More >